Core Country Comparison Shines Spotlight on P&R Trends for Orphan Drugs
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Although orphan drugs are, by definition, targeted at small patient populations, their high prices are such that they can potentially become global blockbusters. In this Strategic Report, GlobalData examines the pricing and reimbursement (P&R) environment for orphan drugs in the seven major markets (7MM): the US, Japan, and the five largest European markets (France, Germany, Italy, Spain, and the UK). This report places them in the context of the wider pharmaceutical market and compares key features, including time to pricing and reimbursement, health technology assessment (HTA) outcomes, and five-year price trends.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Product Type reports